Mullica Hill, NJ – According to filings with the U.S. Securities and Exchange Commission, Durin Technologies is raising $3,500,100.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Benjamin Belinka played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Durin Technologies

At Durin Technologies Inc., we believe that early disease detection is the key to increasing the prospects for successful treatment outcomes. Our focus lies in developing diagnostic tests for the most prevalent and devastating neurodegenerative diseases that make possible both early detection and monitoring of disease progression. Durin Technologies Inc. is a New Jersey-based company developing diagnostic tests for early detection of some of the more pervasive and progressive neurodegenerative diseases. The company was founded by Drs. Robert Nagele and Benjamin Belinka in 2010 and currently resides at the South Jersey Technology Park in Mullica Hill. Our diagnostic strategy takes advantage of the immune system’s unique but consistent reaction to the presence of each type of neurodegenerative disease. Monitoring of disease-linked changes in autoantibody profiles enable identification of biomarkers useful for early disease detection and diagnosis, often much earlier than is possible using any other existing method.

To learn more about Durin Technologies, visit http://www.durintechnologies.com/

Contact:
Benjamin Belinka, President and Chief Executive Officer
856-906 4657
bbelinka@durintechnologies.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved